Grassley questions Auvi-Q’s list price, while Trump shows support for Medicare drug-pricing reform

Although Mylan (NSDQ:MYL) has been under fire for its pricey EpiPen device since August last year, competitor Kaleo found itself garnering unwanted attention from politicians this week over the price of its epinephrine injection, Auvi-Q.

Chairman of the Senate Judiciary Committee, Sen. Chuck Grassley (R-Iowa), wrote a letter to the Richmond, Virginia-based company asking CEO Spencer Williamson to explain the device’s $4,500 price-tag.

Get the full story at our sister site, Drug Delivery Business News.

The post Grassley questions Auvi-Q’s list price, while Trump shows support for Medicare drug-pricing reform appeared first on MassDevice.

from MassDevice http://ift.tt/2nnlWFA